Monte Rosa reported that one of its molecular glue degraders had seen a strong response in immune disorders, but another fell short of expectations.

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. Biomarker-positive patients were rarer than expected in some tumor types ...

In March 2025, Magnet Biomedicine formed a partnership and licensing agreement with Eli Lilly to identify, develop, and market oncology-focused molecular glue therapeutics. In January 2025 ...

Takeda Pharmaceuticals & Degron Therapeutics (May 2024) – Developing novel molecular glue degraders for oncology, neuroscience, and inflammatory diseases. NEOsphere Biotechnologies & Kymera ...

In March 2025, Magnet Biomedicine formed a partnership and licensing agreement with Eli Lilly to identify, develop, and market oncology-focused molecular glue therapeutics. In January 2025, AbbVie and ...